US 11116839
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 11116839 (Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61P, A61P11/00